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Abstract
The emergence of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in the eastern Mediterranean and 
imported cases to Europe has alerted public health authorities. Currently, detection of MERS-CoV in patient 
samples is done by real-time RT-PCR. Samples collected from suspected cases are sent to highly-equipped 
centralized laboratories for screening. A rapid point-of-care test is needed to allow more widespread mobile 
detection of the virus directly from patient material. In this study, we describe the development of a reverse 
transcription isothermal Recombinase Polymerase Amplification (RT-RPA) assay for the identification of MERS-
CoV. A partial nucleocapsid gene RNA molecular standard of MERS-coronavirus was used to determine the 
assay sensitivity. The isothermal (42°C) MERS-CoV RT-RPA was as sensitive as real-time RT-PCR (10 RNA 
molecules), rapid (3-7 minutes) and mobile (using tubescanner weighing 1kg). The MERS-CoV RT-RPA showed 
cross-detection neither of any of the RNAs of several coronaviruses and respiratory viruses affecting humans 
nor of the human genome. The developed isothermal real-time RT-RPA is ideal for rapid mobile molecular MERS-
CoV monitoring in acute patients and may also facilitate the search for the animal reservoir of MERS-CoV.
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Introduction
The analysis of samples in Europe for a case of severe pulmonary syndrome and renal failure in Saudi Arabia led 
to the isolation and characterization of a novel human betacoronavirus termed MERS-CoV 1 . As of November 26
th 68 deaths of 160 laboratory confirmed cases have been recorded by the WHO mainly from countries in the 
Middle East 2. The detection of MERS-CoV infected cases depends primary on sensitive real-time RT-PCR 3 . In 
developing countries, facilities for performing real-time RT-PCR are limited to centralized laboratories. The time 
to result can therefore be long and in many cases last up to several days. A portable, rapid, cheap, and 
sensitive test is needed to identify infected acute cases and would help to improve the onsite search for animal 
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reservoirs.
In recent years a variety of isothermal amplification methods have been developed which offer the possibility of 
developing rapid nucleic acid detection assays for simple point-of-care systems. The recombinase polymerase 
amplification (RPA) assay is an isothermal amplification technology 4. RPA assays run at 42°C for 15 minutes 5,6,
7,8. The amplification in the RPA reaction depends on binding of the recombinase to oligonucleotide primers. 
The complex then scans the template DNA for the corresponding sequence and initiates 5´-strand invasion of 
the oligonucleotide at the site of homology. The strand invasion is stabilized by the single strand binding 
protein. The extension of the primer ensues via a strand displacing DNA polymerase 6,7,8. Real-time detection 
is possible via an exo-probe system 5,6,7,8. In this study, MERS-CoV RT-RPA assay was developed to amplify 
and detect in real-time a fragment of the nucleocapsid gene (NC) of MERS-CoV.
Materials and Methods
Viral RNA. Viral RNA are listed in table 1. MERS-CoV was provided by Ron Fouchier, Erasmus University, 
Rotterdam, Netherlands and the sample preparation was performed at the Robert Koch-Institut in Berlin, 
Germany under the ECDC Framework Service Contract Ref. No. ECDC/2008/011. The respiratory viral RNA panel 
for cross reactivity was provided by Landesgesundheitsamt Niedersachsen, Germany and Brunhilde Schweiger, 
National Reference Center for influenza viruses, Robert Koch Institute, Berlin, Germany.
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Table 1. Viral RNA tested.
The MERS-CoV RT-RPA assay only detected the MERS-CoV RNA, but not other viruses causing similar clinical picture. CT
, cycle threshold; TT, threshold time in minute.
Sample RNA real-time RT-PCR specific assay RT-RPA
Reference Specific assays (Mean 
Ct) TT [min]
Coronaviruses
MERS-CoV 13 36.10 6.70
229E 14 12.6 Negative
NL63 15 14.06 Negative
OC43 14 22.99 Negative
SARS 16 14.21 Negative
Respiratory Viruses
A/California/04/2009 H1N1 18 23.69 Negative
A/Wellington/1/04 H3N2 25.5 Negative
A/dk/Germany R603/06 H5N1 24.4 Negative
B/Malasiya/2506/04 (Victoria 
lineage)
21.2 Negative
B/Iangsu/10/03 (Yamagata lineage) 24.5 Negative
Parainfluenza virus 1 (patient 
isolate) 17
28.09 Negative
Parainfluenza virus 2 (patient 
isolate)
27.81 Negative
Parainfluenza virus 3 (patient 
isolate)
29.13 Negative
Parainfluenza virus 4a (patient 
isolate)
In-house test 21.39 Negative
Parainfluenza virus 4b (patient 
isolate)
28.05 Negative
Respiratory syncytial virus A Provided by National Reference Center for influenza 
viruses, Robert Koch Institute, Germany
Negative
Respiratory syncytial virus B Negative
Human rhinovirus A 89 Negative
Human rhinovirus A 1B Negative
Human rhinovirus B 37 Negative
Real-time RT-PCR and RT-RPA amplicon design. Using the MERS-CoV sequence (GenBank accession 
number: JX869059), we designed NC real-time RT-PCR primers and Taqman probe, and RT-RPA primers and an 
exo-probe (Table 2) to amplify the NC gene. All oligonucleotides were produced by TIBMOLBIOL, Berlin, 
Germany.
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Table 2. Primers and probes for the construction of molecular standard, NC real-time RT-PCR and RT-RPA assay
COR12 UP/DP are NC gene amplification primers; COR12 NC FP/RP/P, NC real-time RT-PCR primers and Taqman probe 
(FAM/TAMRA); COR12 RT-RPA FP/RP, RPA forward and reverse primer; COR12 RT-RPA P, exo-probe; BTF, B: thymidine 
nucleotide carrying Blackhole quencher-1, T: tetrahydrofuran spacer, F: thymidine nucleotide carrying Fluorescein; 
Phosphate, 3’phosphate to block elongation.
Name Primers and probes 
COR12 UP AATGATTCAGCTATTGTTACACAATTCG
COR12 DP ATCTTTCTTAGTGATTACTTTTGGCTGC
COR12 NC FP CAATAGTCAATCATCTTCAAGAGCCTC
COR12 NC RP GGAGAAGTGCCGCGGGTA
COR12 NC P AAACTCTTCCAGATCTAGTTCACAAGGTTCAAGATC
COR12 RT-RPA FP AACTTCCACATTGAGGGGACTGGAGGCAA
COR12 RT-RPA RP AGAGTTTCCTGATCTTGAACCTTGTGAACT
COR12 RT-RPA P TCTTCAAGAGCCTCTAGCTTAAGCAGAAAC-BTF-TCCAGATCTAGTTC-P
RNA standard and RT-RPA conditions. The NC gene was amplified using COR12 UP and COR12 DP (Table 2) 
(nt 28989-29291 of GenBank accession number: JX869059). The amplificate was ligated into plasmid pCRII 
(Invitrogen, Darmstadt, Germany). RNA was transcribed, quantified, diluted into a dilution range from 107 to 101
RNA molecules/µl and tested by real-time RT-PCR as described 10. RT-RPA was performed in a 50 µl volume 
using the TwistAmp™ exo kit (TwistDx, Cambridge, UK) 420 nM RPA primers, 120 nM exo-probe, 2 µM DTT, 14 
mM magnesium acetate, TwistAmpTM rehydration buffer, 2 U Transcriptor (Roche, Mannheim, Germany), 20 U 
RiboLock RNase inhibitor (Fisher, Schwerte, Germany), and 19 mM DTT (Roche). All reagents except for the 
template or sample RNA and magnesium acetate were prepared in a mastermix, which was distributed into 
each tube of the 0,2 ml reaction eight-tube strip containing a dried enzyme pellet. Magnesium acetate was 
pipetted into the tube lids. Subsequently, 5 µl sample was added to the tubes. The lids were closed and the 
magnesium acetate centrifuged into the tubes using a minispin centrifuge and the tubes immediately placed 
into the tubescanner device (Qiagen Lake Constance, Stockach, Germany). Fluorescence measurements were 
performed in an ESEquant tubescanner at 42°C for 10 minutes. A combined threshold and signal slope analysis 
were used for signal interpretation which can be confirmed by 2nd derivative analysis (Tubescanner studio 
software, Qiagen Lake Constance, Stockach, Germany).
Determination of sensitivity and specificity.The sensitivity of the NC real-time RT-PCR assay and the RT-
RPA assay was tested using the quantitative RNA standard in 8 replicates, the threshold time was plotted 
against molecules detected and a semi-log regression was calculated using the Prism software (Graphpad 
Software Inc., San Diego, California) and a probit regression were calculated using the Statistica software 
(StatSoft, Hamburg, Germany).
Sensitivity was additionally evaluated using RNA extracts from dilutions of MERS-CoV virus culture supernatant. 
The supernatant containing 6.3 x 108 genome equivalents/ml (ge/ml) as determined by the UpE real-time RT-
PCR 13 was diluted in tenfold steps. RNA was extracted from these dilutions using the (QIAamp viral RNA mini 
kit, Qiagen, Hilden, Germany) and eluted in 200 µl nuclease free water. A volume of 2.5 µl were tested 
simultaneously in three real-time RT-PCR assays (UpE 13 , Orf1A 3, NC) and the RT-RPA assay. For cross 
detection studies RNA of coronaviruses and other respiratory viruses listed in table 1 were tested.
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Results
A 303 nt standard RNA was produced via in vitro transcription from a plasmid containing a NC gene fragment of 
MERS-CoV. The sensitivity was determined using a dilution range of 107-101 RNA molecules/µl of the MERS-CoV 
RNA standard. The NC real-time RT-PCR and the RT-RPA assay showed a sensitivity of 101 RNA molecules 
detected (Figure 1 and 2). The probit regression predicted a sensitivity of 21 and 10 RNA molecules respectively 
for RT-RPA (figure 3) and NC RT-PCR assay.
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Fig. 1: MERS-CoV RT-RPA assay.
Over time development of fluorescence using a dilution range of 107-101 molecules/µl of the RNA molecular 
standard (Tubescanner Studio Software, Qiagen, Germany). MERS-CoV RT-RPA assay sensitivity is 10 copies 
and yielded results in maximum 7 minutes. 107 represented by black line; 106, gray; 105, red; 104, blue; 103
, green; 102, cyan; 101, dark khaki; negative control, orange. No fluorescence signals was measured for one 
minute (after 3 minutes of the start of the reaction) because of the need of mixing the content.
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Fig. 2: Analytical sensitivity of MERS-CoV NC real-time RT-PCR and RT-RPA.
The analytical sensitivity was determined on RNA molecular standard (8 runs) for real-time RT-PCR (A) and 
real-time RT-RPA (B). Both assays have a sensitivity of 10 RNA molecules. The RT-RPA assay was much 
faster than the RT-PCR as the run time of the RT-RPA is between 3-7 minutes for 107 and 101molecules, 
respectively. While the RT-PCR needed up to 2 hours. Consequently, RT-PCR results is linear, while RT-RPA 
not.
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Fig. 3: Probit regression analysis of MERS-CoV RT-RPA assay
The probit analysis was performed using Statistica software on data of the eight runs of 107-101 RNA 
molecular standard. The limit of detection at 95% probability (21 RNA molecules) is depicted by a Rhomboid.
Using a ten-fold serial dilution of RNA extracted from MERS-CoV tissue culture supernatant, the UpE real-time 
RT-PCR assays 13 detected down to a dilution of 10-6, whereas the Orf1A 3 and NC real-time RT-PCR assays as 
well as the RT-RPA assay detected RNA down to a dilution of 10-5, corresponding to 7.5 genome 
equivalents/reaction (3000 genome equivalents/ml) (Table 3). The RT-RPA assay specificity was determined 
using several coronaviruses and respiratory viruses (Table 1) as well as human genome. None of them were 
detected.
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Table 3. Sensitivity of RT-RPA assay in comparison with three real-time RT-PCR assays
Ten-fold serial dilution of RNA extracted from MERS-CoV culture supernatant was used. UD is undetected; CT, cycle 
threshold; TT, threshold time in minute
Genome equivalence/reaction Real-time RT-PCR RT-RPA
UpE 13 Orf1A 3 NC
Cт Mean Cт Mean Cт Mean TT Mean
9.92E+04 21.97 23.93 22.02 4.30
1.23E+04 25.10 27.14 24.84 4.70
1.30E+03 28.58 31.32 28.37 5.00
9.66E+01 32.50 36.49 31.63 5.50
7.5E+00 36.43 40.91 36.29 6.30
1.14E+00 39.76 UD UD UD
Discussion
The MERS-CoV causing a severe respiratory disease erupted in the Near East last year. In outbreak situations, 
rapid diagnostic tools can generally help to confirm infection in suspected patients and to test contacts in order 
to contain spread of the infectious agent. For wide scale testing, robust field-deployable test systems provide an 
advantage and allow testing in make shift laboratories or at an outbreak site.
The performance of the isothermal RT-RPA assay for the detection of MERS-CoV RNA described here equals that 
of a published real-time RT-PCR assay 3 in terms of sensitivity and specificity at a run time of only 10 minutes. 
RNA concentrations in samples collected from MERS-CoV-infected patient between days 11-16 of infection were 
1.2 x106, 5370, 2691, and 1031, for lower respiratory tract, oronasal swabs, urine, and stool, respectively 11. 
Therefore, the detection limit of our RT-RPA assay (10 RNA copies) is ideal for identifying MERS-CoV. 
Unfortunately, no clinical samples were available in our hand to test.
The run time of the RT-RPA was 10 minutes (figure 1 and 2B), and including nucleic acid extraction from 
samples, results can therefore be obtained in about 30 minutes. Reagents are available as dried pellets (cost 4 
Euro/test) and the detection device is comparably cheap (around 4500 Euro). Rapid point-of-care diagnosis and 
field investigations are feasible as recent use of this technology during the FMDV outbreak in Egypt in 2012 has 
shown 5. We recently successfully operated a mobile RT-RPA unit consisting of a nucleic acid extraction kit, a RT-
RPA kit, a pipette set, a magnetic separator, a tubescanner, and a laptop in Kedougou, Senegal using a solar 
panel (manuscript in preparation). The experiences made indicate that mobile RT-RPA is a very good alternative 
for mobile point-of-care detection, since infrastructure and equipment needs are below that of laboratory based 
or mobile RT-PCR 6,7,8.
During the Hajj, around three million pilgrims from allover the world visit Mecca, Saudi Arabia for an average of 
ten days . Physical stress on the pilgrims may increase the susceptibility to diseases 12 and the density of the 
susceptibles might therefore be conducive to transmission of MERS-CoV. Therefore, implementation of mobile 
RT-RPA units during the Hajj might be an easy tool to detect MERS-CoV infected cases on site to identify acute 
cases and prevent the spread of the virus. RT-RPA might also help to improve affordable monitoring for MERS-
CoV by public health laboratories worldwide.
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